Antares Pharma Company Profile (NASDAQ:ATRS)

About Antares Pharma

Antares Pharma logoAntares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: Health Care Supplies
  • Exchange: NASDAQ
  • Symbol: ATRS
  • CUSIP: 03664210
Key Metrics:
  • Previous Close: $2.31
  • 50 Day Moving Average: $2.25
  • 200 Day Moving Average: $1.85
  • 52-Week Range: $0.67 - $2.67
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -24.10
  • P/E Growth: -0.17
  • Market Cap: $373.76M
  • Outstanding Shares: 155,086,000
  • Beta: 0.88
Profitability:
  • Net Margins: -53.11%
  • Return on Equity: -45.93%
  • Return on Assets: -33.43%
Debt:
  • Current Ratio: 2.40%
  • Quick Ratio: 2.08%
Additional Links:
Companies Related to Antares Pharma:

Analyst Ratings

Consensus Ratings for Antares Pharma (NASDAQ:ATRS) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.50 (3.73% upside)

Analysts' Ratings History for Antares Pharma (NASDAQ:ATRS)
Show:
DateFirmActionRatingPrice TargetDetails
8/13/2016Piper Jaffray CompaniesReiterated RatingOverweight$3.00 -> $2.00View Rating Details
5/10/2016Jefferies Group LLCReiterated RatingBuy$3.00View Rating Details
9/25/2015Oppenheimer Holdings, Inc.Reiterated RatingBuy$4.00View Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Antares Pharma (NASDAQ:ATRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2017        
11/9/2016Q316($0.03)($0.04)$11.15 million$13.50 millionViewListenView Earnings Details
8/9/2016Q216($0.04)($0.04)$11.00 million$12.20 millionViewN/AView Earnings Details
5/9/2016Q1($0.03)($0.05)$11.10 million$12.30 millionViewN/AView Earnings Details
3/8/2016Q415($0.03)($0.04)$12.53 million$11.80 millionViewN/AView Earnings Details
11/5/2015Q3 15($0.03)($0.04)ViewN/AView Earnings Details
8/10/2015Q215($0.03)($0.01)$10.93 million$14.40 millionViewListenView Earnings Details
5/11/2015Q115($0.04)($0.05)$9.22 million$8.30 millionViewListenView Earnings Details
3/12/2015Q414($0.05)($0.08)$8.50 million$8.40 millionViewN/AView Earnings Details
11/6/2014($0.07)($0.05)ViewN/AView Earnings Details
8/7/2014Q214($0.07)($0.07)$6.43 million$6.30 millionViewN/AView Earnings Details
5/9/2014Q114($0.05)($0.07)$6.17 million$5.20 millionViewN/AView Earnings Details
3/13/2014Q413($0.05)($0.04)$6.20 million$4.70 millionViewN/AView Earnings Details
11/6/2013Q313($0.04)($0.05)$5.86 million$5.50 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.03)($0.04)$5.82 million$5.84 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.03)($0.03)$5.12 million$4.50 millionViewN/AView Earnings Details
3/13/2013Q4 2012($0.03)($0.04)$5.36 million$5.50 millionViewN/AView Earnings Details
11/7/2012Q312($0.03)($0.03)$5.62 million$5.68 millionViewN/AView Earnings Details
8/8/2012($0.03)($0.03)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Antares Pharma (NASDAQ:ATRS)
Current Year EPS Consensus Estimate: $-0.17 EPS
Next Year EPS Consensus Estimate: $-0.10 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.04)($0.04)($0.04)
Q2 20161($0.04)($0.04)($0.04)
Q3 20162($0.03)$0.02($0.01)
Q4 20161($0.03)($0.03)($0.03)
Q1 20171($0.04)($0.04)($0.04)
Q2 20171($0.03)($0.03)($0.03)
Q3 20171($0.02)($0.02)($0.02)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Antares Pharma (NASDAQ:ATRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Antares Pharma (NASDAQ:ATRS)
Insider Ownership Percentage: 10.77%
Institutional Ownership Percentage: 33.60%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/9/2016Fred M PowellInsiderBuy100,000$2.03$203,000.00View SEC Filing  
3/21/2016Peter J GrahamSVPBuy20,000$0.77$15,400.00View SEC Filing  
3/18/2016James E FickenscherCFOBuy135,000$0.72$97,200.00View SEC Filing  
3/18/2016Leonard S JacobDirectorBuy50,000$0.72$36,000.00View SEC Filing  
3/18/2016Robert F AppleCEOBuy60,000$0.72$43,200.00View SEC Filing  
9/30/2015James E FlynnMajor ShareholderSell249,998$1.69$422,496.62View SEC Filing  
9/29/2015James E FlynnMajor ShareholderSell225,048$1.82$409,587.36View SEC Filing  
9/28/2015James E FlynnMajor ShareholderSell1,353,483$1.81$2,449,804.23View SEC Filing  
8/24/2015Robert P Roche JrDirectorBuy5,000$1.77$8,850.00View SEC Filing  
8/13/2015Robert P Roche JrDirectorBuy5,000$1.94$9,700.00View SEC Filing  
7/20/2015James E FlynnInsiderSell231,793$2.17$502,990.81View SEC Filing  
7/8/2015James E FlynnMajor ShareholderSell444,341$2.05$910,899.05View SEC Filing  
7/7/2015James E FlynnMajor ShareholderSell198,651$2.09$415,180.59View SEC Filing  
7/6/2015James E FlynnMajor ShareholderSell191,513$2.12$406,007.56View SEC Filing  
7/1/2015James E FlynnInsiderSell713,222$2.09$1,490,633.98View SEC Filing  
6/30/2015James E FlynnMajor ShareholderSell608,691$2.08$1,266,077.28View SEC Filing  
6/29/2015James E FlynnMajor ShareholderSell60,695$2.18$132,315.10View SEC Filing  
6/26/2015James E FlynnInsiderSell756,852$2.27$1,718,054.04View SEC Filing  
6/23/2015James E FlynnInsiderSell499,895$2.39$1,194,749.05View SEC Filing  
6/18/2015James E FlynnInsiderSell478,366$2.44$1,167,213.04View SEC Filing  
6/15/2015James E FlynnInsiderSell748,030$2.44$1,825,193.20View SEC Filing  
3/23/2015Leonard S JacobDirectorSell23,500$2.68$62,980.00View SEC Filing  
9/10/2014Eamonn P HobbsCEOBuy9,000$2.20$19,800.00View SEC Filing  
8/13/2014Robert P Roche JrDirectorBuy5,000$1.96$9,800.00View SEC Filing  
8/11/2014Marvin SamsonDirectorBuy25,000$2.00$50,000.00View SEC Filing  
12/9/2013Paul WottonCEOSell64,100$4.00$256,400.00View SEC Filing  
10/14/2013Robert AppleCFOSell22,000$5.05$111,100.00View SEC Filing  
9/3/2013Anton GuethDirectorSell25,000$4.42$110,500.00View SEC Filing  
9/3/2013Paul WottonCEOSell35,000$4.41$154,350.00View SEC Filing  
8/1/2013Anton GuethDirectorSell25,000$4.41$110,250.00View SEC Filing  
8/1/2013Paul K WottonCEOSell35,000$4.42$154,700.00View SEC Filing  
7/1/2013Anton GuethDirectorSell25,000$4.15$103,750.00View SEC Filing  
7/1/2013Paul K WottonCEOSell35,000$4.14$144,900.00View SEC Filing  
6/25/2013Eamonn P HobbsDirectorSell23,500$4.19$98,465.00View SEC Filing  
6/4/2013Robert F AppleCFOSell115,000$4.02$462,300.00View SEC Filing  
6/3/2013Anton GuethDirectorSell25,000$4.01$100,250.00View SEC Filing  
6/3/2013Kaushik J DaveEVPSell48,000$4.01$192,480.00View SEC Filing  
6/3/2013Paul K WottonCEOSell125,000$4.01$501,250.00View SEC Filing  
5/31/2013Thomas J GarrityDirectorSell13,000$4.08$53,040.00View SEC Filing  
5/17/2013Leonard S JacobDirectorSell17,000$4.00$68,000.00View SEC Filing  
11/16/2012Leonard S JacobDirectorBuy10,000$3.44$34,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Antares Pharma (NASDAQ:ATRS)
DateHeadline
News IconStock Perspective: Antares Pharma, Inc. (NASDAQ:ATRS) Earnings in View - Aiken Advocate (NASDAQ:ATRS)
aikenadvocate.com - February 23 at 3:44 PM
News IconStock Spotlight: Looking at the Levels for Antares Pharma, Inc. (NASDAQ:ATRS) - BVN (NASDAQ:ATRS)
bvnewsjournal.com - February 23 at 3:44 PM
finance.yahoo.com logoBiotech Acquisitions on the Rise in 2017: Latest Reports on Antares Pharma and ACADIA Pharmaceuticals (NASDAQ:ATRS)
finance.yahoo.com - February 21 at 9:59 AM
News IconTwo Stocks on Trader's Radar: Antares Pharma Inc. (NASDAQ ... - The Newburgh Press (NASDAQ:ATRS)
newburghpress.com - February 18 at 3:38 PM
News IconAnalysts believe Antares Pharma, Inc. (NASDAQ:ATRS) is worth $2.67 per share - OracleTimes (NASDAQ:ATRS)
oracletimes.com - February 16 at 3:46 PM
News IconABR Of Antares Pharma, Inc. (NASDAQ:ATRS) Stock At 1 - Stock Observer (NASDAQ:ATRS)
www.thestockobserver.com - February 16 at 3:46 PM
News IconAntares Pharma, Inc. (ATRS): Analyst Rating Changes and PT Levels - Post Analyst (NASDAQ:ATRS)
postanalyst.com - February 16 at 3:46 PM
News IconThe Bears And Bulls Square Off On Antares Pharma, Inc. (ATRS) - NY Stock News (NASDAQ:ATRS)
nystocknews.com - February 16 at 3:46 PM
News IconAntares Pharma, Inc. (NASDAQ:ATRS) Projected to Achieve EPS Of ... - Stock Observer (NASDAQ:ATRS)
www.thestockobserver.com - February 14 at 2:16 AM
News IconStock Check: Reviewing the Numbers for Antares Pharma Inc. (ATRS) - Rives Journal (NASDAQ:ATRS)
rivesjournal.com - February 13 at 9:14 PM
News IconStock Levels in Review for Antares Pharma Inc. (ATRS) - Davidson Register (NASDAQ:ATRS)
davidsonregister.com - February 11 at 2:16 AM
News IconStock Survey: Antares Pharma, Inc. (NASDAQ:ATRS) - Benton Bulletin (NASDAQ:ATRS)
bentonbulletin.com - February 11 at 2:16 AM
investornewswire.com logoEPS Evaluate Of Antares Pharma, Inc. (NASDAQ:ATRS) At $0.06 - Investor Newswire (NASDAQ:ATRS)
www.investornewswire.com - February 9 at 3:49 PM
News IconInvestor Corner: Checking the Charts for Antares Pharma Inc. (ATRS) - Rives Journal (NASDAQ:ATRS)
rivesjournal.com - February 8 at 3:34 PM
News IconLevels in Focus for Antares Pharma Inc. (ATRS) - Piedmont Register (NASDAQ:ATRS)
piedmontregister.com - February 8 at 3:34 PM
News IconInvestor Notebook: Focusing in on Shares of Antares Pharma Inc. (ATRS) - Sherwood Daily (NASDAQ:ATRS)
sherwooddaily.com - February 4 at 1:54 AM
News IconStock Under Wall Street Review: Antares Pharma Inc. (NASDAQ:ATRS) - The Oracle Examiner (NASDAQ:ATRS)
oracleexaminer.com - February 3 at 8:51 PM
News IconQuarterly Sales Analysis of Antares Pharma, Inc. (NASDAQ:ATRS) - The Newburgh Press (NASDAQ:ATRS)
newburghpress.com - February 3 at 3:51 PM
News IconIncrease in Volatility Draws Attention to Shares of Antares Pharma, Inc. (NASDAQ:ATRS) - Nelson Research (NASDAQ:ATRS)
nelsonobserver.com - February 2 at 3:45 PM
News IconTechnical Trading: Focus on Shares of Antares Pharma Inc. (ATRS) - Sherwood Daily (NASDAQ:ATRS)
sherwooddaily.com - February 2 at 3:45 PM
seekingalpha.com logoAntares Pharma: Realistic Expectations (NASDAQ:ATRS)
seekingalpha.com - February 1 at 8:56 PM
News IconInvestor Box: Viewing Levels on Shares of Antares Pharma Inc. (ATRS) - Sherwood Daily (NASDAQ:ATRS)
sherwooddaily.com - February 1 at 3:51 PM
News IconAre Analysts Forecasting a Near-Term Upswing For Antares Pharma, Inc. (NASDAQ:ATRS)? - Wall Street Beacon (NASDAQ:ATRS)
wsbeacon.com - February 1 at 3:51 PM
News IconWhat is the Sell-side Saying About Antares Pharma, Inc. (NASDAQ:ATRS)? - Aiken Advocate (NASDAQ:ATRS)
aikenadvocate.com - February 1 at 3:51 PM
News IconWilliams %R Check on Shares of Antares Pharma Inc. (ATRS) - Sherwood Daily (NASDAQ:ATRS)
sherwooddaily.com - January 31 at 3:54 PM
News IconActive Volume Stock: Antares Pharma Inc. (NASDAQ:ATRS) - HugoPress (NASDAQ:ATRS)
hugopress.com - January 31 at 3:54 PM
News IconStock to Track: Antares Pharma Inc (NASDAQ:ATRS) - Post Registrar (NASDAQ:ATRS)
postregistrar.com - January 31 at 3:54 PM
News IconDelving into Shares of Antares Pharma, Inc. (NASDAQ:ATRS) - Prospect Journal (NASDAQ:ATRS)
prospectjournal.com - January 31 at 2:48 AM
News IconAntares Pharma Inc. (NASDAQ:ATRS) now has Insider Ownership of 8 (NASDAQ:ATRS)
flapship.com - January 30 at 9:47 PM
News IconHigh Volatility Moving the Needle For Shares of Antares Pharma, Inc. (NASDAQ:ATRS) - Wall Street Beacon (NASDAQ:ATRS)
wsbeacon.com - January 30 at 4:47 PM
News IconStock Scrambling Higher Out of The Gate: Antares Pharma, Inc. (NASDAQ:ATRS) - Aiken Advocate (NASDAQ:ATRS)
aikenadvocate.com - January 30 at 4:47 PM
News IconChecking the Levels on Shares of Antares Pharma, Inc. (NASDAQ:ATRS) - The Tribune (NASDAQ:ATRS)
lakecitytribune.com - January 30 at 4:47 PM
News IconTrading Views: RSI, MA, and ADX Review for Antares Pharma Inc. (ATRS) - Sherwood Daily (NASDAQ:ATRS)
sherwooddaily.com - January 30 at 4:47 PM
News IconVolatility Watch on Shares of Antares Pharma, Inc. (NASDAQ:ATRS) - Gilbert Daily (NASDAQ:ATRS)
gilbertdaily.com - January 29 at 8:41 PM
investornewswire.com logoStrong Sell Recommendations Of Antares Pharma, Inc. (NASDAQ:ATRS) At 0 - Investor Newswire (NASDAQ:ATRS)
www.investornewswire.com - January 29 at 1:43 AM
News IconEarnings in Full Force, Analysts Take Aim at Antares Pharma, Inc. (NASDAQ:ATRS) - Wall Street Beacon (NASDAQ:ATRS)
wsbeacon.com - January 27 at 9:51 PM
News IconInvestors are Keeping Tabs on Antares Pharma, Inc. (NASDAQ:ATRS) - The Tribune (NASDAQ:ATRS)
lakecitytribune.com - January 27 at 4:51 PM
News IconIndicator Level Summary for Antares Pharma Inc. (ATRS) - Sherwood Daily (NASDAQ:ATRS)
sherwooddaily.com - January 27 at 4:51 PM
biz.yahoo.com logoANTARES PHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:ATRS)
biz.yahoo.com - January 27 at 4:51 PM
News IconHeady Investors are Taking a Look at Antares Pharma, Inc. (NASDAQ:ATRS) - Prospect Journal (NASDAQ:ATRS)
prospectjournal.com - January 26 at 9:06 PM
News IconNarrowing in on Chart Levels for Antares Pharma Inc. (ATRS) - Sherwood Daily (NASDAQ:ATRS)
sherwooddaily.com - January 26 at 4:06 PM
News IconWhich Direction is This Stock Headed? Update on Antares Pharma, Inc. (NASDAQ:ATRS) - Prospect Journal (NASDAQ:ATRS)
prospectjournal.com - January 25 at 8:52 PM
News IconWatching the Technicals on Shares of Antares Pharma Inc. (ATRS) - Sherwood Daily (NASDAQ:ATRS)
sherwooddaily.com - January 25 at 8:52 PM
News IconCCI Focus on Shares of Antares Pharma Inc. (ATRS) - Sherwood Daily (NASDAQ:ATRS)
sherwooddaily.com - January 25 at 3:49 PM
News IconAntares Pharma, Inc. (NASDAQ:ATRS) Stock ABR At 1 - Stock Observer (NASDAQ:ATRS)
www.thestockobserver.com - January 25 at 3:49 PM
News IconArmistice Capital LLC Position in Antares Pharma INC (ATRS) Cut by $3.13 Million as Market Value Rose (NASDAQ:ATRS)
randolphguide.com - January 24 at 4:10 PM
capitalcube.com logoAntares Pharma, Inc. – Value Analysis (NASDAQ:ATRS) : January 24, 2017 (NASDAQ:ATRS)
www.capitalcube.com - January 24 at 4:10 PM
investornewswire.com logoAntares Pharma, Inc. (NASDAQ:ATRS) Records An Impact Score Of 83 - Investor Newswire (NASDAQ:ATRS)
www.investornewswire.com - January 23 at 3:46 PM
News IconTrading Radar: Checking Technicals for Antares Pharma Inc. (ATRS) - Sherwood Daily (NASDAQ:ATRS)
sherwooddaily.com - January 23 at 3:46 PM
realistinvestor.com logoEPS Projection Of Antares Pharma, Inc. (NASDAQ:ATRS) At $0.06 - RealistInvestor.com (NASDAQ:ATRS)
www.realistinvestor.com - January 23 at 3:46 PM

Social

What is Antares Pharma's stock symbol?

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

Where is Antares Pharma's stock going? Where will Antares Pharma's stock price be in 2017?

2 analysts have issued twelve-month price objectives for Antares Pharma's shares. Their predictions range from $2.00 to $3.00. On average, they expect Antares Pharma's stock price to reach $2.50 in the next twelve months.

When will Antares Pharma announce their earnings?

Antares Pharma is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.

Who owns Antares Pharma stock?

Antares Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Broadfin Capital LLC (8.36%), Armistice Capital LLC (7.09%), Perceptive Advisors LLC (1.88%), Renaissance Technologies LLC (1.84%), Kingdon Capital Management L.L.C. (1.30%) and Rubric Capital Management LP (0.75%). Company insiders that own Antares Pharma stock include Fred M Powell, James E Fickenscher, James E Flynn, Leonard S Jacob, Peter J Graham, Robert F Apple and Robert P Roche Jr.

Who sold Antares Pharma stock? Who is selling Antares Pharma stock?

Antares Pharma's stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Armistice Capital LLC, Janus Capital Management LLC, Alyeska Investment Group L.P., J. Goldman & Co LP, Baird Financial Group Inc., National Planning Corp and State Street Corp.

Who bought Antares Pharma stock? Who is buying Antares Pharma stock?

Antares Pharma's stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Rubric Capital Management LP, Kingdon Capital Management L.L.C., JW Asset Management LLC, Renaissance Technologies LLC and Oxford Asset Management. Company insiders that have bought Antares Pharma stock in the last two years include Fred M Powell, James E Fickenscher, Leonard S Jacob, Peter J Graham, Robert F Apple and Robert P Roche Jr.

How do I buy Antares Pharma stock?

Shares of Antares Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Antares Pharma stock cost?

One share of Antares Pharma stock can currently be purchased for approximately $2.41.

Antares Pharma (NASDAQ:ATRS) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Antares Pharma (NASDAQ:ATRS)

Earnings History Chart

Earnings by Quarter for Antares Pharma (NASDAQ:ATRS)

Dividend History Chart

Dividend Payments by Quarter for Antares Pharma (NASDAQ:ATRS)

Last Updated on 2/25/2017 by MarketBeat.com Staff